Fresenius Expands European Production Capacity to Strengthen Healthcare Supply Chain Resilience
Fresenius is expanding and modernizing its European manufacturing network through new production capabilities for intravenous (IV) fluids in Poland and Italy, strengthening the company’s ability to support reliable supplies of essential healthcare products across the region.
The company has opened a new IV fluids production line at its facility in Kutno, Poland, while also expanding manufacturing and warehouse infrastructure at its Isola della Scala site in Italy. The two projects represent a combined investment of €54 million and are designed to increase local production capacity, strengthen healthcare supply chains and support the continued availability of essential medicines for hospitals and patients throughout Europe.
The investments form part of Fresenius’ broader strategy to build a more resilient manufacturing footprint and bring production closer to the healthcare systems and patients it serves. Over the past five years, the company has invested more than €1 billion in European production capabilities.
The expansion comes at a time when healthcare systems are dealing with increasing demand, complex supply networks and the need for dependable access to critical medicines and healthcare products. By expanding manufacturing capacity within Europe, Fresenius is seeking to strengthen the ability of its facilities to respond to these demands while supporting long-term supply security.
Expanding IV Fluid Production in Poland
The opening of a new IV fluids production line in Kutno represents an important addition to Fresenius’ manufacturing capabilities in Poland.
IV fluids are essential products used across hospitals and healthcare settings. They can play an important role in patient treatment, hydration and the administration of medicines, making reliable availability a key consideration for healthcare providers.
Increasing production capacity within Europe can help strengthen the regional supply network for these products. The new line allows Fresenius to expand its manufacturing capabilities while supporting its broader local-for-local approach.
Under this approach, the company seeks to manufacture products closer to the patients and healthcare systems that use them. Local production can reduce reliance on distant manufacturing and transportation routes while providing additional flexibility within supply networks.
For hospitals, supply continuity is particularly important because shortages or disruptions involving essential medicines can create operational challenges and potentially affect the delivery of patient care.Fresenius’ investment in Kutno therefore represents more than an increase in manufacturing output. It is also part of a broader effort to create a more resilient European healthcare supply chain.
Strengthening Manufacturing and Warehousing in Italy
Alongside the Polish investment, Fresenius has expanded its manufacturing and warehouse infrastructure in Isola della Scala, Italy.
The expanded infrastructure is expected to increase the site’s capabilities and strengthen its role within Fresenius’ European manufacturing network. Manufacturing and warehouse capacity are closely connected to the ability to maintain reliable product availability, particularly for essential healthcare products that need to reach hospitals and other healthcare providers efficiently.
By investing in both production and storage infrastructure, Fresenius is addressing multiple elements of its supply chain.Additional manufacturing capacity can support increased output, while expanded warehouse infrastructure can provide greater flexibility in managing inventory and distribution requirements.
The investment in Italy, together with the new production line in Poland, demonstrates the company’s strategy of strengthening multiple locations within its European network rather than relying on a single manufacturing base.
€54 Million Investment Across Two European Sites
Together, the projects in Poland and Italy represent €54 million in investment.The investment reflects Fresenius’ decision to direct capital toward manufacturing infrastructure, operational capacity and supply chain resilience.
Healthcare supply chains have become an increasingly important strategic consideration for companies, governments and healthcare providers. Disruptions caused by geopolitical developments, transportation challenges, changing demand or manufacturing constraints can affect the availability of essential products.
A geographically diversified manufacturing network can provide additional resilience by distributing production capabilities across multiple locations.For Fresenius, investments in Kutno and Isola della Scala are part of this broader strategy.
The projects also demonstrate the role of long-term capital investment in maintaining healthcare manufacturing capabilities. Production facilities require continued modernization and expansion as demand changes and manufacturing requirements evolve.
More Than €1 Billion Invested in European Production
The latest projects build on Fresenius’ significant investment in its European manufacturing network.Over the past five years, the company has invested more than €1 billion in European production. The investments cover the infrastructure needed to manufacture healthcare products and support the company’s long-term presence across the region.
Fresenius operates around 20 manufacturing facilities and several research and development centers across Europe.This network gives the company a substantial regional manufacturing footprint across different healthcare businesses.
The strategy reflects Fresenius’ position as a global healthcare company that manufactures many of its products relatively close to the patients and healthcare systems it serves.Maintaining manufacturing capabilities close to end markets can support supply chain flexibility while reducing dependence on long-distance transportation for certain products.
Responding to Changing Healthcare Demand
Healthcare systems across Europe continue to face changing patterns of demand.
Population needs are evolving, healthcare technologies are developing and hospitals are managing increasingly complex treatment requirements. At the same time, healthcare providers expect reliable access to the medicines, nutrition products and medical technologies required to care for patients.
These pressures make manufacturing capacity and supply chain resilience important components of healthcare infrastructure.For manufacturers such as Fresenius, maintaining reliable production requires ongoing investment in facilities, equipment, technology and operational capabilities.
The company’s latest investments in Poland and Italy are designed to help address these requirements while strengthening the foundation of its European operations.
Supporting Security of Supply
Supply security is particularly important for essential healthcare products.Hospitals cannot always substitute one product for another when a critical medicine or medical product becomes unavailable. Maintaining adequate manufacturing and distribution capabilities is therefore an important part of supporting healthcare continuity.
Fresenius’ expansion of IV fluids production directly relates to this issue.By increasing production capacity in Europe, the company can strengthen its ability to supply products to healthcare systems in the region. Additional capacity can also provide greater flexibility when demand changes or unexpected supply chain pressures emerge.
The strategy is consistent with the company’s emphasis on resilient value chains and local manufacturing.Dr. Marc-Alexander Mahl, President of Pharma, Medical Nutrition & Sustainability at Fresenius, emphasized the importance of resilient local production for European healthcare systems.
He described the investments in Poland and Italy as part of Fresenius’ effort to bring essential production closer to patients while advancing its local-for-local strategy and strengthening security of supply.He also highlighted the broader relationship between healthcare and European resilience, noting the importance of reliable value chains to the region’s ability to maintain access to essential healthcare products.
Manufacturing as Part of Healthcare Infrastructure
The investments also illustrate how manufacturing can be considered an important component of healthcare infrastructure.Hospitals and healthcare providers depend on a consistent supply of products to deliver services. While clinical teams are at the center of patient care, the availability of medicines, nutrition products and medical technologies depends on complex manufacturing and distribution systems operating behind the scenes.
A disruption at any point in that system can create challenges for healthcare providers.Manufacturing facilities therefore have a role that extends beyond industrial production. Their output supports healthcare providers and ultimately patients.
Fresenius’ investments in Europe are designed to reinforce that connection by strengthening manufacturing capacity in the same region where many of its products are used.
Supporting the #FutureFresenius Strategy
The investments in Poland and Italy are also aligned with Fresenius’ #FutureFresenius transformation and growth strategy.The company describes its current phase as the “Rejuvenate” phase of the strategy, with a focus on strengthening its core businesses and growth platforms.
Capital allocation is an important part of that approach. By directing investment toward manufacturing expansion, innovation and operational excellence, Fresenius aims to improve the long-term competitiveness of its businesses.The latest projects demonstrate how the strategy is being applied to physical infrastructure.
Rather than focusing solely on financial or organizational transformation, the company is also investing in the manufacturing capabilities required to support future growth.For Fresenius, strengthening production capacity can simultaneously support customer needs, supply chain resilience and the long-term development of its businesses.
European Investment Bank Partnership
The Poland and Italy projects complement Fresenius’ broader European investment program.In 2025, Fresenius signed a €400 million financing agreement with the European Investment Bank (EIB). The agreement supports research and development activities as well as manufacturing expansion within the European Union.
The financing demonstrates the broader scale of investment required to strengthen Europe’s healthcare manufacturing capabilities.Research and development and manufacturing capacity are closely connected. New treatments, technologies and products require the appropriate infrastructure to move from development into commercial production.
Investment in both areas can therefore support the long-term competitiveness of healthcare companies and contribute to the resilience of European healthcare supply chains.
Supporting Pharma, Nutrition and MedTech
Fresenius’ manufacturing strategy extends beyond IV fluids.As part of #FutureFresenius, the company plans to continue investing in the long-term growth and competitiveness of its businesses across pharmaceuticals, nutrition and medical technology.
These businesses serve different areas of healthcare but share a common dependence on reliable manufacturing and distribution networks.
Pharmaceutical products require robust production and quality systems. Medical nutrition products must be manufactured and distributed reliably to healthcare providers and patients. Medical technologies require sophisticated production capabilities and supply networks.Strengthening the infrastructure supporting these businesses can therefore have a broad impact across the healthcare ecosystem.
Building a More Resilient Supply Chain
The concept of supply chain resilience has become increasingly important across healthcare.Modern healthcare supply chains can span multiple countries and involve manufacturers, logistics providers, distributors, hospitals and other organizations. This interconnected structure creates efficiencies but can also introduce vulnerabilities when unexpected disruptions occur.
Increasing local manufacturing capacity is one way companies can strengthen these networks.Fresenius’ investments in Poland and Italy add production and infrastructure within Europe, creating additional capabilities that can support the regional healthcare market.
The strategy does not eliminate every potential supply chain risk, but it can provide additional production capacity and geographic diversification.
A Long-Term Approach to European Manufacturing
The €54 million investment in Kutno and Isola della Scala is part of a much larger, long-term commitment to European manufacturing.With more than €1 billion invested in European production over five years, Fresenius has established manufacturing resilience as a significant element of its business strategy.
The company’s network of approximately 20 manufacturing facilities and several research and development centers provides a foundation for continued investment.The expansion of IV fluid production in Poland and manufacturing and warehouse infrastructure in Italy adds to that foundation.
As healthcare demand continues to evolve, manufacturers will need to balance efficiency with resilience. Production capacity must be sufficient to meet demand while supply chains need enough flexibility to respond to changing circumstances.Fresenius’ latest investments demonstrate the company’s focus on strengthening its European manufacturing footprint while supporting healthcare supply chain resilience.
The new IV fluids production line in Kutno and expanded manufacturing and warehouse infrastructure in Isola della Scala represent a combined €54 million investment. The projects increase local production capabilities and reinforce the company’s ability to support healthcare systems with essential products.
They also form part of a broader investment strategy that has seen Fresenius commit more than €1 billion to European production over the past five years.Through its local-for-local approach, Fresenius is seeking to bring production closer to patients while strengthening the resilience of healthcare supply chains. The company’s investments also align with its #FutureFresenius strategy, which emphasizes the development of core businesses, innovation and operational excellence.
The 2025 €400 million financing agreement with the European Investment Bank further supports Fresenius’ European research, development and manufacturing ambitions.As the healthcare industry continues to face changing demand and increasing supply chain complexity, investment in reliable production infrastructure will remain an important part of ensuring that essential medicines and healthcare products are available when patients and providers need them.
For Fresenius, the expansion in Poland and Italy represents another step in building that infrastructure. By strengthening production capacity, expanding its European manufacturing network and investing in its core healthcare businesses, the company is positioning its operations to support healthcare systems and patients across Europe while pursuing long-term growth and competitiveness.
Source link: https://www.fresenius.com/
